Facebook Reveals Real-World GLP-1 Drug Side Effects: Social Media Pharmacovigilance
Analysis of Facebook mentions of GLP-1 drug adverse events captures patient-reported side effects not fully represented in clinical trials or formal reporting systems.
Quick Facts
What This Study Found
Analysis of Facebook mentions of GLP-1 drug adverse events captures patient-reported side effects not fully represented in clinical trials or formal reporting systems.
Key Numbers
Facebook posts analyzed from 2022-2024, tracking adverse event trends and co-occurrence patterns over the period of rapid GLP-1 drug adoption.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
These findings have practical implications for the growing number of patients using peptide-based therapies.
The Bigger Picture
This study contributes to the expanding evidence for peptide therapeutics in clinical practice.
What This Study Doesn't Tell Us
Study limitations in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to other evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Analysis of Facebook mentions of GLP-1 drug adverse events captures patient-reported side effects no
- Evidence Grade:
- Evidence level based on study design in publication.
- Study Age:
- Published in 2025.
- Original Title:
- Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.
- Published In:
- JMIR infodemiology, 5, e73619 (2025)
- Authors:
- Alibilli, Amrutha S, Jain, Vidur, Mane, Heran, Yue, Xiaohe, Ratzki-Leewing, Alexandria, Merchant, Junaid S, Criss, Shaniece, Nguyen, Quynh C, McCoy, Rozalina G, Nguyen, Thu T
- Database ID:
- RPEP-09866
Evidence Hierarchy
Frequently Asked Questions
What does this mean for patients?
Analysis of Facebook mentions of GLP-1 drug adverse events captures patient-reported side effects not fully represented in clinical trials or formal reporting systems.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09866APA
Alibilli, Amrutha S; Jain, Vidur; Mane, Heran; Yue, Xiaohe; Ratzki-Leewing, Alexandria; Merchant, Junaid S; Criss, Shaniece; Nguyen, Quynh C; McCoy, Rozalina G; Nguyen, Thu T. (2025). Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.. JMIR infodemiology, 5, e73619. https://doi.org/10.2196/73619
MLA
Alibilli, Amrutha S, et al. "Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.." JMIR infodemiology, 2025. https://doi.org/10.2196/73619
RethinkPeptides
RethinkPeptides Research Database. "Harnessing Facebook to Investigate Real-World Mentions of Ad..." RPEP-09866. Retrieved from https://rethinkpeptides.com/research/alibilli-2025-harnessing-facebook-to-investigate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.